Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

Docetaxel has been proved to provide survival benefit for advanced prostate cancer (PCa) patients. Resistance to docetaxel further reduces the survival of these patients. Herein, we performed a comprehensive bioinformatic analysis to identify differentially expressed genes (DEGs) between docetaxel s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rui-ji, Li, Shu-ying-, Liu, Li-quan, Xu, Bin, Chen, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806863/
https://www.ncbi.nlm.nih.gov/pubmed/34077304
http://dx.doi.org/10.1080/21655979.2021.1936831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806863/
https://www.ncbi.nlm.nih.gov/pubmed/34077304
http://dx.doi.org/10.1080/21655979.2021.1936831

Ejemplares similares